Zentexia is a Danish pharmaceutical R&D company specialized in fusion molecules based on secondary metabolites from eukaryotes.
Zentexia develops novel active small molecules for the life science industries through a proprietary interdisciplinary approach based on artificial intelligence (AI).
AI is employed in all stages of structural optimization to provide pioneering pharmacodynamic and pharmacokinetic profiles, minimize development risk and optimize the probability of success. This approach enables the exploration and characterization of a large chemical space.
Zentexia’s novel active small molecules are aimed at a range of life science applications – pharmaceutical as well as adjacent regulatory categories like medical devices.
Zentexia’s primary development programs are focused on pharmacological modulation of senescence and treatment of related pathophysiologies.